These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 22183861)
1. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. Kang CM; Chung YE; Park JY; Sung JS; Hwang HK; Choi HJ; Kim H; Song SY; Lee WJ J Gastrointest Surg; 2012 Mar; 16(3):509-17. PubMed ID: 22183861 [TBL] [Abstract][Full Text] [Related]
2. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01). Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S; Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer. Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409 [TBL] [Abstract][Full Text] [Related]
4. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. Paik WH; Lee SH; Kim YT; Park JM; Song BJ; Ryu JK J Korean Med Sci; 2015 Jul; 30(7):917-23. PubMed ID: 26130955 [TBL] [Abstract][Full Text] [Related]
5. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060 [TBL] [Abstract][Full Text] [Related]
6. Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer. Cho IR; Chung MJ; Bang S; Park SW; Chung JB; Song SY; Seong J; Hwang HK; Kang CM; Lee WJ; Park JY Pancreatology; 2013; 13(5):539-43. PubMed ID: 24075521 [TBL] [Abstract][Full Text] [Related]
7. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma. Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385 [TBL] [Abstract][Full Text] [Related]
11. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection. Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078 [TBL] [Abstract][Full Text] [Related]
13. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322 [TBL] [Abstract][Full Text] [Related]
14. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. Katz MH; Pisters PW; Evans DB; Sun CC; Lee JE; Fleming JB; Vauthey JN; Abdalla EK; Crane CH; Wolff RA; Varadhachary GR; Hwang RF J Am Coll Surg; 2008 May; 206(5):833-46; discussion 846-8. PubMed ID: 18471707 [TBL] [Abstract][Full Text] [Related]
15. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142 [TBL] [Abstract][Full Text] [Related]
16. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter? Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638 [TBL] [Abstract][Full Text] [Related]
18. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234 [TBL] [Abstract][Full Text] [Related]